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Background: We have treated 4 patients of acute erythematous skin diseases with fever and/or pain by H2
enriched intravenous fluid. We also added data from two volunteers for assessing the mode of H2 delivery to the
skin for evaluation of feasibility of H2 treatment for this type of skin diseases.
Methods: All of the four patients received intravenous administration of 500 ml of H2 enriched fluid in 30 min for
more than 3 days except in one patient for only once. From two volunteers (one for intravenous H2 administration
and the other for H2 inhalation), blood samples were withdrawn serially and air samples were collected from a
heavy duty plastic bag covering a leg, before, during and after H2 administration. These samples were checked for
H2 concentration immediately by gas chromatography. Multiple physiological parameters and blood chemistry data
were collected also.
Results: Erythema of these 4 patients and associated symptoms improved significantly after the H2 treatment and
did not recur. Administration of H2 did not change physiological parameters and did not cause deterioration of the
blood chemistry. The H2 concentration in the blood from the volunteers rapidly increased with H2 inhalation and
slowly decreased with cessation of H2 particularly in the venous blood, while H2 concentration of the air from the
surface of the leg showed much slower changes even after H2 inhalation was discontinued, at least during the
time of sample collection.
Conclusion: An improvement in acute erythemtous skin diseases followed the administration of H2 enriched fluid
without compromising the safety. The H2 delivery study of two volunteers suggested initial direct delivery and
additional prolonged delivery possibly from a slowly desaturating reservoir in the skin to the surface.* Correspondence: hirohisa.ono@live.jp
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Severe and acute erythematous skin diseases usually re-
quire immediate medical attention, particularly when the
symptoms involve severe pain and/or fever. Treatment
may have to be initiated before spending enough time
and effort for investigating real causes of the rush or
functional state of the other organs and the steroid
agents tend to be the first choice of the treatment. How-
ever, the complications from the general use of steroid
have been well known and therefore, non-dermatological
clinics like ours frequently encounter difficulty in finding
quick remedies with minimal side effects. Erythema is
reddening of the skin due to inflammatory mechanisms
either as primary culprits or secondary features and lo-
cally released inflammatory cytokines such as TNF-α,
IL-1,8, GM-CSF etc., stimulate phagocytes and inflam-
matory cells and results in production of ROS (reactive
oxygen species)[1, 2]. The interaction between the ROS
and nitric oxide leads to the formation of peroxynitrite
radicals and also by the iron-mediated Fenton reaction,
hydroxyl radicals, both of which are highly reactive and
destructive to the cell membrane and mitochondria and
polyunsaturated fatty acids(PUFAs) [3]. However, ROS
dismutases, which are abundant in the skin and also cur-
rently available medications are ineffective to neutralize
these most destructive radicals except Edaravone [4], of
which use is strictly limited for the treatment of acute
cerebral infarction patients with normal kidney and liver
function. H2 may be useful in these situations because it
immediately and simultaneously neutralizes both perox-
ynitrites and hydroxyl radicals [5] and also H2 is known
to cause no significant side effects since it is produced in
the human intestine as a fermentation process, although
not continuously[6]. We report four cases of acute ery-
thematous skin disease patients who were suffering from
skin rash and also from associated symptoms such as se-
vere pain and/or fever. They were treated with regular
medications first and when the conventional treatments
failed, then, intravenous fluids which contained H2 were
added after a proper consent form was signed. However,
H2 administration may not be therapeutic unless enough
concentration stays at the surface layer of the skin for a
sufficient period and the concentration should be higher
than that of internally produced H2. Two volunteers
participated in a H2 delivery study where H2 concentra-
tion in the blood and in the air at the surface of the skin
was measured before, during and after H2 administra-
tion by inhalation or by intravenous fluid infusion.
Methods
Patients and volunteers
Before recruiting the patients and volunteers to the
current study, a complete PARQ conference was given
to all of the patients and their family and to volunteers.Our specific consent form, which had been approved
by the Nishijima Hospital Ethics Committee and the
Nishijima Hospital Pharmacists Council, was signed be-
fore the study with clear understanding of the nature of
the study.
Case history of 4 patients
Case 1
48 y.o. male who was in good health until 5 days prior
to the admission to Nishijima Hospital when severe pain
and skin rash involving his left side of the face made
him to visit an emergency service where he was diag-
nosed as having herpes simplex infection and was treated
with antivirus agents and pain medications. However,
the pain increased and the left side of the face became
numb. In addition, blisters in the erythematous area coa-
lesced and formed ulcer-like appearance. The patient
also noticed left ptosis and double vision and became
unable to open the mouth, which made oral intake im-
possible. The patient was admitted to the hospital for
deteriorated general condition with dehydration, severe
pain and fever. On admission, the patient was found to
have partial paralysis of the left 3 rd, 5th and 6th cranial
nerves in addition to severe erythema with edema and
small ulcers, covering the left side of the face and frontal
region. The hydration treatment was initiated with 3
bags of 500 ml glucose and electrolyte solution and con-
tinued for 6 days with a decreasing dose during the
hospitalization. Initially, two bags of these solutions
(500 ml) had been enriched with H2. No antibiotic was
given. Before the infusion therapy, the patient was un-
able to open his left eye and the mouth (Figure 1, upper
left). The picture of Figure 1 upper right was taken after
the patient was asked to open his left eye and the mouth.
The patient was unable to do so, except for minimal
opening of the mouth. However, 3 days after the admis-
sion and H2 infusion, the patient’s condition remarkably
improved, including erythema, ulcers, pain level, open-
ing the eye and mouth (Figure 1, lower left) and the
patient became afebrile. Since cranial nerve functions
recovered also and he became able to take oral soft nu-
trients, intravenous hydration was decreased to 2 bags of
H2- enriched glucose-electrolyte solution (esuron B,200 ml/
bag), daily. By the 6th hospital day, the patient was eat-
ing a regular food and his dehydration was corrected.
He had no pain and the severe inflammation of the skin
disappeared. The patient discharged home and no return
of the skin erythema noted during a follow-up period
(Figure 1, lower right).
Case 2
67 y.o male lapsed into coma after a large basilar ar-
tery aneurysm rupture and subarachnoid hemorrhage.
After the aneurysm was surgically clipped, the patient
Figure 1 Erythematous skin disease, Case 1. Before the H2 treatment with severe erythema and edema (upper left), the patient was unable
to open his left eye and the mouth except for a minimal degree with a maximal effort (upper right). Improved conditions, 3 days after the H2
treatment (lower left) with opening eye and mouth. The severe inflammation of the skin almost disappeared in 6 days after H2 treatment
(lower right) and was discharged home and no return of the skin erythema noted during a follow-up period.
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itis, with deterioration of the liver and kidney function.
After multiple medications including antibiotic and anti-
convulsant, his general condition had been stabilized
until 2 months after the surgery when he became febrile
and developed severe skin abnormality. The abnormality
consisted of erythematous papules, severe skin edema,
blisters and vesicles and shedding of the skin. The Stevens-
Johnson syndrome was suspected and he was trans-
ported to a general hospital with dermatology department.
However, the patient was sent back with several diagno-
sis such as drug erythema, thrombocytopenia, possible
trichophyton infection etc. and use of steroid and anti-
fungal cream were recommended but not systemic steroid.However, application of these creams further deterio-
rated the skin condition despite of discontinuation of
suspected drugs and finally, it was decided to use H2-
enriched intravenous fluid. After a complete PARQ with
the patient’s family who signed a consent, H2-enriched
saline solution (500 ml) was given twice a day. Redness
of the skin started fading and swelling and hardness of
the skin from severe edema significantly improved in
3 days. His high fever subsided. After one week of the
hydrogen treatment, the skin lesions almost disappeared
(Figure 2, lower left) and general condition improved
also. Although the patient remained comatose after the
treatment and expired approximately 4 months after the
surgery, the skin lesions did not recur.
Figure 2 Erythematous skin disease, Case 2, 3 and 4. Erythematous skin lesion of the case 3 in the entire face (upper left) started improving
approximately 30 min after the H2 infusion in the left side of the face first (upper-middle) and then in about one hour, the whole face improved
(upper right). Severe swelling and erythema of case 2 subsided in 7 days after H2 treatment (lower left). Finer papules of case 4 started coalescing
(lower middle). In 3 days after H2 treatment (lower right), significant improvement was noted and the skin lesion did not recur.
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48 y.o female started feeling hot sensation in her face
and developed erythema in the entire face (Figure 2,
upper left) after a CT scan study with contrast enhance-
ment for cerebral aneurysm. Drug eruption was suspected
and a minophagenC solution (Minophagen Pharmaceut-
ical Co.) which had been effective in these situations,
was given intravenously. However, the erythema did not
subside and the patient developed fever (38.5○C), head-
aches and nausea. As an emergency measure, two bags
of a 250 ml of saline solution (Terumo Co.), which had
been enriched with H2 was given. Approximately 30 min.
after the infusion, the erythema started fading in the left
side of the face first (Figure 2, upper middle) and then in
about one hour, the whole face improved (Figure 2, up-
per right) and her body temperature started coming
down in about one hour. At that point, the infusion
stopped and the patient returned home. No recurrence
of the skin rush nor fever was noted during a follow-up
period.
Case 4
62 y.o. male had been intubated and mechanically venti-
lated with stable vital signs after severe subarachnoid
hemorrhage from a ruptured cerebral aneurysm until
7 days after the ictus when the patient developed high
fever and erythema which consisted of finer papules
without fusing together. Initially, the patient was treated
with local ointments with steroid but the erythema spread
in the whole body and started coalescing (Figure 2, lower
middle). In 3 days after H2-enriched saline solution was
given twice a day intravenously, the skin lesion startedfading (Figure 2, lower right) and the elevated body tem-
perature normalized.
Volunteers
Two volunteers who were already in Nishijima hospital
with different medical conditions agreed to let the study
to use H2 and their arterial access port and venous port
which had been established for their medical treatment.
The blood samples (1 ml at each time) were withdrawn
from these ports, before, during and after H2 adminis-
tration by intravenous infusion of 500 cm3 of saline or
by inhalation of 2%H2 gas for 20 min followed by inhal-
ation of 4%H2 gas. Both patients and their family under-
stood perfectly that the study will not provide any
benefit to them directly but possibly for the future of H2
treatment research. All the proper PARQ and signing of
the consent form had been done before the initiation of
the study.
Production and administration of H2 enriched
intravenous fluid and H2 gas
H2 enriched intravenous solution was produced by sim-
ply immersing regular intravenous fluid bags in the
hydrogen water tank (Miz. Co, Patent No.4486157, Pa-
tent Gazette of Japan 2010).), as has been reported else-
where [7]. H2 gets in the bag by diffusion through the
bag wall. Therefore, the bag was neither opened nor
altered in anyway and this method eliminated the chance
of contamination completely. Although H2 concentra-
tion in the water tank was stable at the saturation
(0.8 mM), the H2 concentration in the bag varied with
















H2 concentration in IV bags
after immersion in H2 water.






BagA : Thin wall bag
BagB:Thick wall bagBagB
Figure 3 H2 concentration in IV bags after immersion in H2
water. Bag A (with soft and thin wall) vs. Bag B(with hard and thick
wall). Concentration of H2 in BagA reached almost 93% of saturation
in 48 h, while only 76% of saturation occurred in BagB in 48 h.
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(Figure 4). The bag with soft and thin wall shortened the
time required for the content of the bag to reach the sat-
uration. However, the speed of loosing H2 concentration
in these bags was greater than in harder and thicker wall
bags, when the bag was taken out of the tank and
exposed in the air for the intravenous infusion treatment.
However, we have chosen the bags with softer and thin-
ner wall because the H2 concentration, measured at the
tip of the infusion catheter 30 min after the initiation of
infusion, still remained approximately 90% of the ori-
ginal concentration and this was more convenient than
using a harder and thicker wall bag with very long im-
mersion time for saturation. By keeping the H2 enriched
IV bag in another hydrogen water bag or in a bag with
ice water during the infusion, the speed of desaturationLoss of H2concen
(measured at the
Figure 4 Loss of H2 concentration in IV bags. Bag A (with soft and thin
hanged in the air by itself (bare), or in another bag filled with water, or bar
fluid level). The bare bag still retained more than 90% of initial concentratio
occurred with the IV bag in another water-filled bag during the infusion budecreased. However, these arrangements made the simple
intravenous infusion procedure more cumbersome and
complicated than searching and using a larger vein and
finishing rapid intravenous infusion from a bare, soft and
thin bag within 30 min. H2 gas was prepared for inhal-
ation with an apparatus, made in our hospital by Yoji
Nishijima M.D., using a H2 generator (HG200, GL Sci-
ence, Tokyo, Japan), oxygen inlet and an air compressor.
An appropriate concentration of H2 gas was mixed with
the air and additional oxygen as needed and provided to
the patient through a regular facial mask. The patients
inhaled the gas by their own effort and speed but for the
patients, who were on mechanical ventilation, the gas
was given through the respirator.
The production and use of the apparatus and the
intravenous fluid and the gas thus produced were ap-
proved by Nishijima Hospital Pharmacists Council and
were conducted upon the advice from the Council and
Japanese Welfare-Labor Administration (Tokai-Hokuriku
District Bureau) and Sizuoka Prefectural Administration
(Pharmaceutical Affair, Regulatory Audit Section).
H2 delivery study by measuring hydrogen concentration
in the blood and in the air samples from the bag
covering the leg
Ten blood samples were taken (1 cm3 at each time) from
these arterial and venous access ports at 10, 15, 20, 30,
40, 42, 46, 52 min and 58 min after the administration
of H2 and a control blood sample was taken immedi-
ately before the study.
The blood samples were immediately transferred into
a small glass bottle (12 cm3 size) and the top was se-
cured. The bottle was brought to a near-by gas chro-
matograph (TRIlyser, mBA-3000,Taiyo Co Ltd. Osaka,
Japan) for the measurement of H2. For the study of H2
concentration from the skin surface, a leg of thesetration in IV bags
 end of IV line)
wall) vs. Bag B(with hard and thick wall). H2 enriched IV bags were
e but after the gas in the bag evacuated to leave fluid only (no gas/
n at the end of regular infusion (30 min). Delayed desaturation
t the set up and infusion was rather cumbersome.
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tic bag with 1 L of the air. The small glass bottles, used
for the blood samples, were included in the plastic bag
with the top kept open. Then, at the time of measure-
ment during H2 administration, the top of the glass bot-
tle was placed and secured by manipulating the glass
bottle from outside of the transparent bag without open-
ing the bag and the rest of gas in the plastic bag was
suctioned away and replaced each time with 1 L of fresh
air. The bottles with secured top were kept in the plastic
bag until the study was completed because the plastic
bag was tightly taped on the skin. Then, at the end, all
the bottles with secured top were taken out of the plastic
bag by removing the skin tape and were brought for the
measurement of H2 concentration in the bottles by the
gas chromatography. The sampling times of these air in
the plastic bag were, before the study for a control and
at 15, 20, 30, 40 min after starting H2 infusion and an
additional sample was taken at 46 min for the inhalation
study. For the H2 gas inhalation study, a 2%H2 gas was
given for 20 min first and then, 4%H2 gas for additional
20 min. For H2 infusion study, 500 mL of H2 enriched
saline solution was given within 30 min.
Physiological parameters associated with H2
administration
A complete set of the physiological parameters was
studied immediately before, during and after completion
of H2 treatment as a routine procedure. The complete setFigure 5 H2 concentration in the blood and air samples from the skin
administration during 30 min intravenous infusion (right) and 40 min inhal
with 4%H2 gas. Slower changes of H2 concentration are noted in the air sa
arterial and venous blood.of the parameters included 12 indices, such as body
temperature(BT), blood pressure(BP), pulse rate(PR),
oxygen concentration related parameters (pO2(Torr),
sO2, pO2(A-a), pO2(a/A)). carbon dioxide related indices
(pCO2(Torr), HCO3-act(micromole/L), and base excess
related indices BE(ecf,micromole/L), BE(B,micromole/L),
BB(micromole/L).
Results
Erythema of these 4 patients and associated symptoms,
such as intensive pain in the face with neurological deficits
and skin ulcers (case 1), fever and edematous hardening of
the entire body, particularly in the extremities with skin
ulcers (Case 2), rather mild but with acute fever and nausea
and headache (case 3), mild but worsening and spreading
skin lesions with fever (case 4), all improved significantly
after the H2 treatment and did not recur.
The H2 delivery study of two volunteers showed that the
concentration of H2 in the blood rapidly increased with H2
inhalation and slowly decreased with cessation of H2, par-
ticularly in the venous blood. However, H2 concentration
of the air samples in the plastic bag covering a leg showed
much slower changes and continued to increase even after
H2 inhalation was discontinued, at least during the time of
sample collection (Figure 5). The blood level of H2 was sig-
nificantly higher when H2 was given by inhalation as com-
pared to via intravenous route.
Administration of H2 did not change physiological
parameters and did not cause significant deterioration ofsurface. The samples were taken before, during and after H2
ation (left), for 20 min with 2%H2 gas followed by additional 20 min.
mples from the surface of the skin as compared to the changes in the
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already had severe abnormalities before the H2 treat-
ment such as thrombocytopenia of case 2 (Table 1).
Discussion
In neurosurgery, administration of multiple medications
for the treatment of depressed level of consciousness,
elevated intracranial pressure, pneumonia, abnormal di-
uretic hormone etc. are very common and immediate
discontinuation of these regimens due to suspected drug
eruption is rather difficult, if not impossible. It is well
known that in acute erythematous diseases of the skin,
ROS (reactive oxygen species) produced by migrated in-
flammatory cells and others destroy the cell membrane
and aggravate the skin disease [1, 2]. Peroxynitrites and
hydroxyl- radicals are most potent and cannot be elimi-
nated by clinically available medications except only by
edaravone [4]. However, edaravone is approved onlyTable 1 Duration of H2 treatment and lab studies of 4 patien
chemistry
GOT GPT γ-GPT
Case 1 : 6 days
At the beginning 23 58 96
4 days after 16 27 66
9 days after (3 days after resumption) 20 22 63




At the beginning 33 58 253
7 days after 20 57 244
10 days after 27 59 233
2 weeks after 29 46 210
18 days after 19 35 152
3 weeks after 15 22 79
chemistry
GOT GPT γ-GPT
Case 3 : 2hrs
At the beginning 22 25 28
45 days after (45 days after completion) 19 20 25
chemistry
GOT GPT γ-GPT
Case 4 : 3 days
At the begining 25 35 342
2 days after 34 36 286
5 days after (2 days after completion) 60 117 300
Administration of H2 did not change physiological parameters and did not cause si
function, although some of these patients already had severe abnormalities beforefor acute stage of cerebral infarction in Japan and the
high cost of the medication and possibility of side effects
make frequent and prolong use difficult. In addition,
edaravone becomes a radical by itself after neutralizing
the surrounding radicals which needs to be neutralized
by other materials. On the other hand, H2 inactivates
peroxynitrites and hydroxyl radicals directly and immedi-
ately without any risk of side effects and also H2 can be
produced easily with low cost. However, H2 until this
time has been provided in drinking water or as a gas
and could not be administered when oral intake or in-
halation is prohibited from a medical condition.
Recently, a new technique allowed hydrogen to be dis-
solved safely [7] in the bag of intravenous fluid solution
by simply immersing the bag in a H2 water producing
container. H2 gets in the bag by simple diffusion and
therefore, no need for opening the bag or any alteration
of the bag, which eliminates the risk of contaminationts
hematology
T-BIL CRP WBC RBCx104 Plateletx104
0.7 1.51 7800 462 32.2
0.4 1.89 7800 430 36.8
10600 431 52.8
0.19 8000 440 51.6
hematology
T-BIL CRP WBC RBCx104 Plateletx104
0.6 8.27 10200 367 29.1
8.71 18800 297 20.1
9.35 37000 348 3.8
1.9 6.53 11900 288 1.9
1.6 5.81 11200 258 4.6
8.64 17700 310 24.2
hematology
T-BIL CRP WBC RBCx104 Plateletx104
4500 432 13.6
0.4 0.24 4500 439 15.5
hematology
T-BIL CRP WBC RBC (万) Plateletx104
1.31 18000 396 30.6
0.65 21900 381 26
1.91 13200 409 11.7
gnificant deterioration of the blood chemistry such as for liver and kidney
the H2 treatment such as thrombocytopenia of case 2.
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able to drink or swallow and it was thought that H2
could be given only by intravenous route. The safety
monitoring with physiological parameters and laboratory
studies showed no ill effects on those multiple indices
and organ function such as kidney and liver function, by
this method of H2 administration (Table 1). Even in the
case 2 with thrombocytopenia, no other hematological
worsening was noted. Clinical symptoms of the skin dis-
eases of all four patients improved rather rapidly and
significantly. Therefore, it may be reasonable to assume
that H2 infusion in these situations was quite safe and
effective. However, it is still possible that the skin condi-
tion improved for reasons unrelated to H2 administra-
tion since the pattern of improvement was not uniform
and a clear dose response relation could not be obtained.
The clinical effectiveness of hydrogen is usually explained
by its specific scavenger ability against hydroxyradicals
and peroxynitrites. The first line of the defense in the
skin is keratinocytes which are located in the outermost
layer of the skin and known to produce a large quantity
of ROS (reactive oxygen species), primarily for anti-
microbial effects and reduction of microbial virulence
factors at high level [8]. Although many ROS scavengers
and dismutases are present in the skin where severe oxi-
dation continues all the time, it is essential to maintain a
low level ROS for regulatory purposes [9]. These residual
ROS and ROS overflow from overproduction can be the
source of peroxynitrites. In addition, intracellular perox-
ynitrites are generated by the Nox 1 ((NADPH oxidase 1) -
derived ROS and intracellular NO (nitric oxide), since
Nox1 is localized in the nucleus of keratinocytes [10].
Peroxynitrites activates p38MAPK pathways, which are
related to production of inflammatory cytokines, such as
TNF-α and IL-1, and many others [11]. The control of
these intracellular processes by diffusible H2 is import-
ant and thus H2 may have reduced the level of inflam-
mation seen in erythematous skin disease. In the present
H2 concentration study, the blood concentration was
much lower when H2 was given via intravenous route as
compared to inhalation. However, in the both modes of
H2 administration, the arterial blood concentration was
elevated first and then venous blood but the H2 concen-
tration in the air around the skin increased very slowly
and then continued to increase even after H2 adminis-
tration by inhalation stopped. These findings may imply
that the slowness is related to the slow blood flow com-
partment [12] and/or permeability barrier of lipid-water
layers of the skin tissue itself [13] and also that the skin
may function as a reservoir for a prolonged release of
H2. The slow but prolonged release of H2 directly from
the skin is most advantageous as a therapeutic regimen
of the skin diseases, since the erythematous skin disease
involves outermost layer of the skin which is exposed tocontinuous oxidation and possesses rather scarce blood
vessels. If the production of ROS is continuous, the de-
livery of H2 needs to be longer. The skin with a slower
desaturation compartment provides better opportunity
for utilization of intravenous infusion as a useful route
for H2 administration, since the slower compartment
may accumulate more H2 with prolonged administration
rather than higher concentration with relatively shorter
administration, such as by inhalation. Intravenous ad-
ministration of H2 was more convenient and consistent
from our experience, since it was usually difficult to keep
a facial mask on conscious but neurologically compro-
mised patients for a prolonged time for H2 inhalation.
The limitations of our study include small number of
patients and volunteers. Our conclusions from the re-
sults of this study need to be confirmed by a study with
more patients and volunteers. Possibility of presence of a
slow H2 desaturation compartment in the skin needs to
be examined with a much longer study time. Because
this study was done on volunteers, our study time was
limited and too short for the analysis of the slow releas-
ing compartment. In addition, no tissue biopsy was done
from the skin. Therefore, no final diagnosis of the skin
disease was available. Future studies will clarify those is-
sues and provide a best selection of H2 delivery method
based upon the nature of the disease and the condition
of the patient.
In summary, erythema of these 4 patients and asso-
ciated symptoms, such as intensive pain in the face with
neurological deficits and skin ulcers, fever and edema-
tous hardening of the entire body, rather mild but with
acute fever and nausea and headache, mild but worsening
and spreading skin lesions with red rush all improved
significantly after the H2 treatment and did not recur.
The H2 delivery study of two volunteers showed that the
concentration of H2 in the blood rapidly increased with
H2 inhalation and slowly decreased with cessation of H2,
particularly in the venous blood. However, H2 concentra-
tion of the air samples in the plastic bag covering a leg
showed much slower changes and continued to increase
even after H2 inhalation was discontinued, at least during
the time of sample collection.Competing interests
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